| Identification | Back Directory | [Name]
INDEX NAME NOT YET ASSIGNED | [CAS]
2130869-21-3 | [Synonyms]
Mal-(CH2)5-Val-Cit-PAB-Eribulin | [Molecular Formula]
C69H97N7O19 | [Molecular Weight]
1328.54 |
| Hazard Information | Back Directory | [Biological Activity]
Mal-(CH2)5-Val-Cit-PAB-Eribulin is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB[1].
Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules[2]. | [References]
[1]. Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. Patent US20170252458A1. [2]. Watanabe K, et, al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4; 10(2): 161-174. |
|
|